Sviluppa biotherapeutici vivi basati sul microbioma come co-terapia oncologica.
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Series A Munich-based mbiomics closed the third and final 12M EUR tranche of its Series A (30M EUR in total) with MIG Fonds and Bayern Kapital for microbial production facilities. | $13.9M |